Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma

This study tests whether adding a drug called elranatamab (a bispecific antibody that directs immune cells to kill myeloma cells) before and after a stem cell transplant can improve outcomes for high-risk multiple myeloma patients. The treatment is used to "purge" remaining cancer cells and then prevent the disease from coming back. **You may be eligible if...** - You are between 18 and 75 years old - You have newly diagnosed, high-risk multiple myeloma and are eligible for a stem cell transplant - Your myeloma responded at least partially to initial treatment - You have adequate organ function **You may NOT be eligible if...** - You have already received a prior stem cell transplant - You have active serious infections or autoimmune conditions - Your organ function is too compromised to safely receive treatment Talk to your doctor to see if this trial is right for you.